



EXECUTIVE SUMMARY

January 1, 2024

K2X Technology & Life Science, Inc. (“K2X”), a novel FinTech entity, believes it offers a unique, statistical and safer way for the world to invest in pure innovation – top tier early-stage start-ups. Offering a Non-Correlated investment class, with Higher Returns, Lower Risk with Ultimate Liquidity and Global Diversification!

- ***K2X is a Silicon Valley-based FinTech offering global investors a novel, safer, higher-return, non-correlated, diversified, and liquid (assuming NASDAQ IPO completed) way to invest in the best angel-stage start-ups.***
- ***Investments are thoroughly double-vetted – first by a lead investor, usually a sophisticated angel group, who sets the terms, then by a panel from K2X’s 100+ “world class advisors,” all of whom are also investors in K2X.***
- ***Investing since 2018, K2X seeks to create an ETF-like vehicle whose assets are a large number of start-ups – 85+ portfolio companies to date - 75% in life science - diversified by both industry and geography with investments in the US, Canada, Israel and India.***
- ***Superior results – budding unicorns, three exits, and anticipating 25-30% annual IRR.***
- ***K2X investors are stockholders (not LP’s) with no cash calls, management fees or carry.***
- ***If you own 1% of K2X, you own 1% of all the assets, including any new investments.***
- ***K2X’s statistical model increases the probability of any startup to succeed.***
- ***Management incentive is only stock options, so interests are fully aligned with investors!***
- ***K2X is seeking registration to enable listing on NASDAQ in 2024.***
- ***K2X’s goal is to become “The ETF of Start-Ups” for global investors.***
- ***K2X is raising \$5-10 million via a very favorable convertible debt round with interest while you wait, and a 25% discount on the IPO conversion.***

K2X is a private Delaware-incorporated investment company focused on creating an ETF-like vehicle of diversified and thoroughly vetted start-ups thus defining an entirely new **non-correlated** asset class. The Company has raised \$17 million from Series A and Series B preferred shares, as well as common shares and the accelerated exercise of certain warrants and options, and the ongoing convertible debt round.

K2X’s current portfolio consists of 85+ life science, technology, and industrial early-stage start-up companies in the US, Canada, Israel, and India, and soon Australia. K2X is focused on finding the best start-ups it believes are most likely to succeed using an effective double-vetting methodology. The Company began investing in early 2018 and many investments have experienced new financings at substantially higher valuations. K2X portfolio investments have experienced three exits to date, including BasePaws which was acquired by Zoetis (NASDAQ: ZTS) which yielded a 12X return on the initial investment. The Company believes that several of its portfolio companies may have unicorn potential. Please visit www.k2x.capital to see the entire portfolio, management, Board of Directors, Screening Committee Chairs and the 100+ world-class advisors who assist in due diligence.

K2X is in the process of engaging an investment banking team, and meeting with family offices. It is in the process of seeking registration under the Investment Company Act of 1940 which would enable listing on the NASDAQ and raising \$50+ million. K2X intends to operate as a Business Development Company and distribute excess cash from exits, if any, quarterly to shareholders.

Paul M. Russo, PhD - CEO

c: +1 (408) 605-7695
paul@k2x.capital

www.k2x.capital

Simon Westbrook - CFO

c: +1 (408) 313-5830
simon@k2x.capital